We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2008 by Denver Research Institute.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00733174
First Posted: August 12, 2008
Last Update Posted: August 12, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
GlaxoSmithKline
Information provided by:
Denver Research Institute
August 8, 2008
August 12, 2008
August 12, 2008
March 2004
January 2009   (Final data collection date for primary outcome measure)
Effect of rosiglitazone vs. placebo on exercise tolerance [ Time Frame: 18 months ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance
Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance
Subjects with impaired glucose tolerance will be randomized to either rosiglitazone or placebo for a 18 month period. The study will look at baseline, 12 month and 18 month data for exercise tolerance, coronary artery calcification and diabetes indicators.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Impaired Glucose Tolerance
  • Drug: Rosiglitazone
    tablet
  • Drug: Placebo
  • Experimental: 1
    Rosiglitazone
    Intervention: Drug: Rosiglitazone
  • Placebo Comparator: 2
    Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
60
Not Provided
January 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects must sign the informed consent to participate in the study.
  • Male or female adults ages 25-75 years.
  • Female subjects must be postmenopausal (i.e., > 6 months without menstrual period), surgically sterile, or using effective barrier contraceptive measures (Intra-Uterine Device (IUD), diaphragm with spermicide or condom with spermicide).
  • Women of childbearing potential must use effective barrier contraceptive measures for at least 1 month prior to visit 1, and should continue to use the same contraceptive method during the study and for 30 days after discontinuing study medication.
  • Female subjects of childbearing potential must have a negative urine pregnancy test.
  • Subjects must have an FPG < 126 mg/dL at Screening 1 AND Screening 2, a C-peptide > 2.0 ng/mL and a HbA1c <6.5%.
  • Subjects must have a Body Mass Index 25-40 (must be < 300 lbs).
  • Subjects must have a 2 hour post-prandial glucose 140-199 mg/dL at Screening 1 AND Screening 2. If the 2 hour post-prandial glucose result is 130-139 mg/dL at Screening 2, subjects will be allowed to repeat the OGTT.

Exclusion Criteria:

  • Women who are lactating, pregnant, or planning to become pregnant during the study will be excluded.
  • Women using hormone contraception or on hormone replacement therapy will be excluded.
  • Subjects with any clinically significant abnormality identified on the Screening physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study will also be excluded.
  • Use of any other investigational agents or participation in any other investigational studies during the study period will not be allowed.
  • Patients will also be excluded if there is a presence of clinically significant hepatic disease or patient with LFT levels > 2 times the upper limit of normal laboratory range
  • Subjects with a documented history of significant hypersensitivity (e.g., difficulty swallowing, difficulty breathing, tachycardia or skin reaction) to thiazolidinediones
  • Subjects with any contraindications to rosiglitazone
  • Presence of unstable or severe (New York Heart Association-NYHA class 3 or 4) angina, including angina requiring continual nitrate treatment for symptomatic relief, or coronary insufficiency
  • Subjects with HYHA class 3 or 4 of congestive heart failure requiring drug therapy; systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg
  • History of cancer (except non-melanomatous skin carcinoma)
  • Active alcohol or drug abuse within the last 6 months
  • Subjects with chronic diseases requiring periodic or intermittent treatment with oral or intravenous corticosteroids
  • Subjects who are unable to understand dosing directions or swallow study medications
  • Subjects who are currently smoking
  • Subjects unable to adhere to protocol requirements.
  • Persons with angina or any other cardiac or pulmonary symptoms that would potentially limit exercise performance will be excluded.
  • Persons taking prescription or over-the-counter weight loss medications or persons on a weight loss program with ongoing weight loss, or starting an intensive exercise program within 30 days of screening will also be excluded.
Sexes Eligible for Study: All
25 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00733174
101797
COMIRB NO: 03-755
Yes
Not Provided
Not Provided
Jane Reusch, MD, Denver Research Institute
Denver Research Institute
GlaxoSmithKline
Not Provided
Denver Research Institute
August 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP